Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
| Author | |
|---|---|
| Abstract |
:
Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma. |
| Year of Publication |
:
2018
|
| Journal |
:
The Lancet. Oncology
|
| Date Published |
:
2018
|
| ISSN Number |
:
1470-2045
|
| DOI |
:
10.1016/S1470-2045(18)30006-8
|
| Short Title |
:
Lancet Oncol
|
| Download citation |
